Pregabalin as a Treatment for Seizures or Neuropathic Pain

Pharmacist CEU
Contact Hours: 2.0 (0.2 CEUs)

Course Summary

Pregabalin is a drug that has Food and Drug Administration (FDA) approval for the treatment of neuropathic pain, including pain that is associated with spinal cord injury and diabetic peripheral neuropathy (DPN). It also has received FDA approval for fibromyalgia and postherpetic neuralgia. For patients with epilepsy, pregabalin is approved as an adjunctive treatment for partial-onset seizures in patients 1 month of age and older. This course provides insights into the various indications, potential adverse effects, and dosing in individuals suffering from diverse nervous system maladies that result in the prescribing of pregabalin.

Course Objectives

Identify the approved indications for pregabalin

Describe the different dosage forms and dosing frequencies for pregabalin

Identify the potential side effects associated with pregabalin

List some patient education points for patients who are prescribed pregabalin

I. Introduction

II. History of Pregabalin

III. Clinical Pharmacology of Pregabalin

1. Mechanism of Action
2. Pharmacokinetics

IV. Dosage and Administration

1. Labeled Uses
2. Off-label Uses
3. Administration

Contraindications, Warnings, and Adverse Reactions

1. Angioedema
2. Cardiovascular
3. Central Nervous System
4. Creatine Kinase (CK) Levels
5. Hematologic
6. Ophthalmologic
7. Peripheral Edema
8. Suicidal Behavior and Ideation
9. Tumorigenic Potential
10. Weight Gain
11. Recreational Drug Use and Substance Use Disorder
12. Withdrawal

V. Post-marketing Experience

VI. Drug Interactions

VII. Specific Populations

1. Pregnancy
2. Lactation
3. Pediatric Use
4. Geriatric Use
5. Renal Impairment

VIII. Lookalike/Soundalike Concerns

IX. Storage and Handling

X. Patient Education Pearls

XI. Summary

How to Earn Credit:
To earn credit for this course, participants must:
  1. Read the course objectives and faculty planner disclosure
  2. Read the course material
  3. Complete the post-test with a minimum score of 70% and complete the course evaluation form.
  4. Results are automatically submitted to CPE Monitor

Faculty Planner Disclosure

The following individuals were involved in developing this activity: Steven Malen, PharmD, MBA, and Pamela Sardo, PharmD, BS. Pamela Sardo, Pharm.D., B.S., was an employee of Rhythm Pharmaceuticals until March 2022 and has no conflicts of interest or relationships regarding the subject matter discussed. There are no financial relationships relevant to this activity to report or disclose by any of the individuals involved in the development of this activity.

Unlabeled Use Disclosures

The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of LLC. LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.

Computer Hardware/Software Requirements

Please ensure the device you plan to use meets these requirements and specifications:

  • Operating System: Windows 7,8,10, or 11 /Mac OS X 10.9 or later/iOS/Android
  • Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
  • A connection to the internet
  • For Live Webinars or Conferences: GoToWebinar application for iOS, Android, Mac, or PC. You cannot 'call into' a live conference.

  • Target Audience: Pharmacist
  • Contact Hours: 2.0 (0.2 CEUs)
  • Activity Release Date: 6/14/2023
  • Activity Expiration Date: 6/14/2026
  • Activity Type: Knowledge
  • UAN: 0669-0000-23-082-H01-P
  • Topic: Disease State Management/Drug Therapy
  • CeBroker Number: 20-1079156


Steve Malen, PharmD, MBA



The logo for the Accreditation Council for Pharmacy Education (ACPE)., LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

‹‹ Back to Course List